About ACGT
Judah Folkman, M.D.
Director of The Vascular Biology Program,
Children's Hospital;
Andrus Professor of Pediatric Surgery
and Professor of Cell Biology;
Harvard Medical School and Children's Hospital,
Boston, Massachusetts
Director of The Vascular Biology Program,
Children's Hospital;
Andrus Professor of Pediatric Surgery
and Professor of Cell Biology;
Harvard Medical School and Children's Hospital,
Boston, Massachusetts
Ten angiogenesis inhibitors are currently approved by the FDA in the U.S., and several angiogenesis inhibitors are also approved in 30 other countries for the treatment of cancer and macular degeneration. In addition, more than 20 angiogenesis inhibitors are currently in clinical trials in the U.S. and other countries.
Dr. Folkman's exceptional achievements have been recognized by numerous national and international awards. In 1990 he was elected to the National Academy of Sciences. He is also a member of the American Academy of Arts and Sciences, the American Philosophical Society and the Institute of Medicine. He holds honorary degrees from 17 universities.
Dr. Folkman is the author of more than 400 peer-reviewed papers as well as many other publications. In the December 2005 issue of Nature, Peter Carmeliet wrote that "Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments."
< Return to Scientific Advisory Council
©2007 Alliance for Cancer Gene Therapy 96 Cummings Point Road, Stamford, CT, 06902